Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 8.6%
Pacific Biosciences of California (NASDAQ:PACB) Stock Price Down 8.6%
Pacific Biosciences of California, Inc. (NASDAQ:PACB – Get Rating)'s stock price dropped 8.6% during mid-day trading on Tuesday . The company traded as low as $6.23 and last traded at $6.35. Approximately 56,064 shares changed hands during mid-day trading, a decline of 99% from the average daily volume of 5,694,436 shares. The stock had previously closed at $6.95.
美国加州太平洋生物科技公司(纳斯达克代码：PACB-GET Rating)周二午盘股价下跌8.6%，最低报6.23美元，尾盘报6.35美元。午盘，约56,064股股票易手，较日均成交量5,694,436股下跌99%。该股此前收盘报6.95美元。
Analyst Upgrades and Downgrades
分析师升级和下调评级
PACB has been the subject of a number of research analyst reports. Canaccord Genuity Group decreased their target price on Pacific Biosciences of California from $17.00 to $14.00 and set a "buy" rating for the company in a research note on Friday, August 5th. Piper Sandler decreased their target price on Pacific Biosciences of California from $7.50 to $6.00 in a research note on Sunday, August 21st. Finally, Cowen reduced their price objective on Pacific Biosciences of California to $8.00 in a research report on Tuesday, August 9th. One analyst has rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the stock. According to data from MarketBeat, Pacific Biosciences of California presently has an average rating of "Moderate Buy" and an average price target of $22.00.
PACB已经成为许多研究分析师报告的主题。Cancord Genuity Group在8月5日(星期五)的一份研究报告中将其对加州太平洋生物科学公司的目标价从17.00美元下调至14.00美元，并对该公司设定了“买入”评级。派珀·桑德勒在8月21日周日的一份研究报告中将他们对加州太平洋生物科学公司的目标价从7.50美元下调至6.00美元。最后，考恩在8月9日星期二的一份研究报告中将他们对加州太平洋生物科学公司的目标价格下调至8.00美元。一位分析师对该股的评级为卖出，一位分析师给出了持有评级，四位分析师给出了买入评级。根据MarketBeat的数据，加州太平洋生物科学公司目前的平均评级为“中等买入”，平均目标价为22.00美元。
Pacific Biosciences of California Stock Down 0.2 %
加州太平洋生物科学公司股价下跌0.2%
The firm has a market cap of $1.38 billion, a P/E ratio of -6.66 and a beta of 1.33. The company has a quick ratio of 11.07, a current ratio of 11.50 and a debt-to-equity ratio of 1.31. The firm has a fifty day moving average of $5.78 and a 200-day moving average of $6.68.
该公司的市值为13.8亿美元，市盈率为-6.66，贝塔系数为1.33。该公司的速动比率为11.07，流动比率为11.50，债务权益比为1.31。该公司的50日移动均线切入位在5.78美元，200日移动均线切入位在6.68美元。
Institutional Trading of Pacific Biosciences of California
加州太平洋生物科学公司的机构交易
Several institutional investors and hedge funds have recently bought and sold shares of PACB. Advisor Group Holdings Inc. raised its stake in Pacific Biosciences of California by 71.4% in the fourth quarter. Advisor Group Holdings Inc. now owns 14,522 shares of the biotechnology company's stock valued at $299,000 after buying an additional 6,050 shares during the period. Envestnet Asset Management Inc. bought a new stake in Pacific Biosciences of California in the fourth quarter valued at approximately $410,000. Bank of America Corp DE raised its stake in Pacific Biosciences of California by 75.5% in the fourth quarter. Bank of America Corp DE now owns 455,984 shares of the biotechnology company's stock valued at $9,330,000 after buying an additional 196,212 shares during the period. HighTower Advisors LLC raised its stake in Pacific Biosciences of California by 11.9% in the fourth quarter. HighTower Advisors LLC now owns 90,885 shares of the biotechnology company's stock valued at $1,862,000 after buying an additional 9,646 shares during the period. Finally, Teacher Retirement System of Texas raised its stake in Pacific Biosciences of California by 25.2% in the fourth quarter. Teacher Retirement System of Texas now owns 37,011 shares of the biotechnology company's stock valued at $757,000 after buying an additional 7,450 shares during the period.
几家机构投资者和对冲基金最近买卖了PACB的股票。Advisor Group Holdings Inc.在第四季度增持了加州太平洋生物科学公司的股份71.4%。Advisor Group Holdings Inc.现在持有这家生物技术公司14,522股股票，价值29.9万美元，在此期间又购买了6,050股。Envestnet Asset Management Inc.在第四季度购买了加州太平洋生物科学公司的新股份，价值约41万美元。第四季度，美国银行(Bank Of America Corp DE)将其在加州太平洋生物科学公司的持股比例提高了75.5%。美国银行DE现在拥有455,984股生物技术公司的股票，价值9,330,000美元，在此期间又购买了196,212股。HighTower Advisors LLC在第四季度将其在加州太平洋生物科学公司的持股增加了11.9%。HighTower Advisors LLC现在持有这家生物技术公司90,885股股票，价值1,862,000美元，在此期间又购买了9,646股。最后，德克萨斯州教师退休系统在第四季度将其在加州太平洋生物科学公司的持股比例提高了25.2%。德克萨斯州的教师退休系统现在拥有37,011股这家生物技术公司的股票，价值757,000美元，在此期间又购买了7,450股。
Pacific Biosciences of California Company Profile
加州太平洋生物科学公司简介
(Get Rating)
(获取评级)
Pacific Biosciences of California, Inc designs, develops, and manufactures sequencing systems to resolve genetically complex problems. The company provides PacBio's Systems, which conduct, monitor, and analyse biochemical sequencing reactions; consumable products, including single molecule real-time (SMRT) cells; and various reagent kits designed for specific workflow, such as template preparation kit to convert DNA into SMRTbell double-stranded DNA library formats, including molecular biology reagents, such as ligase, buffers, and exonucleases.
加州太平洋生物科学公司设计、开发和制造测序系统，以解决基因复杂的问题。该公司提供进行、监测和分析生化测序反应的PacBio系统；消耗品，包括单分子实时(SMRT)细胞；以及为特定工作流程设计的各种试剂盒，如将DNA转化为SMRTbell双链DNA文库格式的模板制备试剂盒，包括连接酶、缓冲液和核酸外切酶等分子生物学试剂。
Featured Articles
专题文章
- Get a free copy of the StockNews.com research report on Pacific Biosciences of California (PACB)
- Is This Medical Gear Maker Ready To Continue Its Rally?
- The Five (5) Hottest Stocks To Watch Ahead Of Q3 Earnings
- Has Take-Two Interactive Devolved into a One-Trick Pony?
- Four Cheap Stocks With Interesting Insider Activity
- Is Lyft Going To Make It As Acquisition Rumors Swirl?
- 免费获取StockNews.com关于加州太平洋生物科学的研究报告(PACB)
- 这家医疗设备制造商准备好继续反弹了吗？
- 第三季度财报公布前最值得关注的五(5)只股票
- Take-Two Interactive是否已经退化为一招小马？
- 具有有趣内幕活动的四只廉价股票
- 随着收购传言的甚嚣尘上，Lyft能否成功？
Receive News & Ratings for Pacific Biosciences of California Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pacific Biosciences of California and related companies with MarketBeat.com's FREE daily email newsletter.
获得《加州日报》太平洋生物科学的新闻和评级-在下面输入您的电子邮件地址，通过MarketBeat.com的免费每日电子邮件时事通讯接收对加利福尼亚州太平洋生物科学公司和相关公司的最新新闻和分析师评级的每日简要摘要。